[redacted]

Date: 16 May 2022, 9.00 to 10.00

Participants: A.I.S.E: [redacted]@aise.eu, [redacted]@aise.eu **Cosmetics Europe:** [redacted]@cosmeticseurope.eu, [redacted] **IFRA:** [redacted]@ifrafragrance.org, [redacted]@ifrafragrance.org.

Questions:

- The representatives asked what the "safe use"/minimal exposure derogation procedure could look like.
- It was stated that a general ban on MHC would pose a threat to the cosmetics industry in Europe, making a route for exceptions necessary.
- The representatives inquired how the simplification of procedures will work concerning essential uses

COM answers:

- The "safe use" or minimal exposure concept is still an open discussion; what a derogation could look like is to be determined in a next step.
- The concept has to be designed in a way which makes "safe use" or minimal exposure an exceptional route adjacent to the essential use concept.
- Essentiality concerns explicitly the function of the substance in the product.
- A simplification of the processes will be achieved through derogations of general applicability as well as through the implementation of initial screening steps which could cut out lengthy technical/scientific discussions and assessments regarding clearly essential or non-essential uses. Discussions on this are still ongoing.
- Way forward: The impact assessment is due by the end of July, the submission of the proposal in Q4 22 or Q1 23.